When exploring the primary causes of hepatocellular carcinoma, many people assume heavy alcohol consumption tops the list. However, clinical data shows that viral hepatitis and liver cancer are far more inextricably linked.

According to epidemiological data from the Korean Association for the Study of the Liver, alcohol is not the leading trigger. Instead, chronic hepatitis B accounts for roughly 61% of liver cancer cases. Hepatitis C drives another 15%. Together, these viral infections cause more than 76% of all liver malignancies diagnosed nationwide.

Liver cancer remains a major cause of cancer-related mortality. Preventing this disease requires moving beyond lifestyle warnings about alcohol. Patients and clinicians must focus on early viral detection and timely antiviral intervention.

Why Is Alcohol Blamed When Viruses Drive the Disease?

Public health campaigns often emphasize the dangers of heavy alcohol intake. Alcohol certainly accelerates hepatic fibrosis and triggers alcoholic steatohepatitis. Yet, oncogenic viruses cause direct genetic and cellular alterations within hepatocytes.

Hepatitis B virus (HBV) integrates its viral DNA directly into host chromosomes. This process induces genomic instability. It can trigger cellular proliferation even before advanced cirrhosis develops. In contrast, hepatitis C virus (HCV) causes relentless necroinflammation and oxidative stress. Over decades, this damage leads to cirrhosis and neoplastic transformation.

Heavy drinking significantly compounds these risks. An individual with chronic viral hepatitis who drinks heavily faces an exponential surge in cancer risk. Still, the underlying viral infection remains the primary driver. Blaming alcohol alone creates a false sense of security among non-drinkers who may harbor an undiagnosed viral infection.

Is a Normal Liver Enzyme Level Truly Safe for Hepatitis B?

For decades, clinicians relied heavily on serum alanine aminotransferase (ALT) levels to guide treatment decisions. An elevated ALT level signals active hepatocellular injury. Conversely, a normal ALT level often reassured patients that their liver remained healthy.

Modern hepatology has overturned this assumption. Normal ALT levels do not guarantee that the liver is free from disease progression. The virus can replicate actively while blood enzyme levels stay completely normal. Sustained viral replication continues to inflict low-grade histological damage and genetic mutations.

The revised 2026 Korean Association for the Study of the Liver clinical guidelines reflect this paradigm shift:
* HBV DNA supersedes ALT alone: Clinicians now prioritize viral load measurements over transaminase fluctuations.
* Expanded treatment window: Antiviral therapy is now recommended for patients with moderate viremia. This applies when serum HBV DNA falls between 2,000 IU/mL and 100,000,000 IU/mL, regardless of whether ALT levels are elevated.
* Proactive oncologic risk reduction: Waiting for liver enzymes to spike allows silent fibrosis to accumulate unchecked.

Clinical research confirms the value of this early strategy. In a long-term cohort study evaluating chronic hepatitis B patients with moderate viremia and minimally elevated ALT, early oral antiviral therapy reduced major adverse liver events by roughly 80%. This composite endpoint included hepatocellular carcinoma, hepatic decompensation, liver transplantation, and all-cause mortality.

How Have Clinical Indications for Hepatitis B Shifted?

Deciding when to start lifelong antiviral therapy requires weighing long-term compliance against oncologic risk. Hepatology protocols have evolved from reactive monitoring to proactive suppression.

Traditional Management Protocol
- Monitored ALT until values reached twice the upper limit of normal.
- Delayed antiviral therapy if liver enzymes remained within normal laboratory reference ranges.
- Relied on physical signs of advanced cirrhosis before initiating aggressive suppression.
Modern Guideline-Directed Algorithm
- Analyzes serum HBV DNA viral load as the primary risk biomarker.
- Initiates oral antivirals at lower viral thresholds to prevent chronic inflammation.
- Incorporates non-invasive fibrosis assessments such as transient elastography and platelet biomarkers.
- Considers family history of hepatocellular carcinoma as an independent risk modifier.

Starting potent oral nucleos(t)ide analogues suppresses viral replication rapidly. Complete viral suppression halts the progression of fibrosis. In many cases, it even enables partial regression of existing fibrous tissue.

What Clinical and Structural Barriers Delay Timely HBV Treatment?

Despite clear clinical evidence supporting early intervention, treatment gaps remain widespread. Nationwide clinical registry data from Korea indicates that only 22.2% of individuals diagnosed with chronic hepatitis B receive antiviral treatment.

A primary contributor to this gap is the discrepancy between clinical practice guidelines and national insurance reimbursement criteria:
* Reimbursement restrictions: National health insurance systems frequently mandate both marked ALT elevation and elevated viral load before granting drug coverage.
* The self-pay dilemma: Patients who meet guideline criteria for early therapy but fall outside reimbursement rules must pay out-of-pocket for lifelong medication.
* Premature disengagement: Patients frequently stop attending follow-up visits because normal routine check-ups convince them that their infection is harmless.

When clinical treatment is delayed until biochemical damage manifests, the risk of irreversible cirrhosis escalates. Updating insurance reimbursement parameters to mirror clinical trial data remains an urgent public health priority.

Can Hepatitis C Be Eliminated Before Cancer Develops?

Unlike hepatitis B, chronic hepatitis C does not integrate into the host genome. Furthermore, medicine now possesses curative therapy. Direct-acting antiviral (DAA) regimens achieve sustained virologic response rates exceeding 95% within 8 to 12 weeks of oral therapy.

Achieving a cure effectively prevents liver failure. It also dramatically lowers future liver cancer risk. However, eliminating hepatitis C requires closing gaps in the diagnostic and care cascade.

National Screening Initiatives
- Routine antibody screening identifies exposure in high-prevalence cohorts.
- National screening data in individuals aged 56 identified hundreds of hidden infections, showing a prevalence four times higher than in younger cohorts.
The Diagnostic Drop-off Problem
- An HCV antibody test indicates lifetime exposure, not necessarily an active infection.
- Active infection must be confirmed using a reflex HCV RNA quantitative test.
- National screening evaluations show that only 44.9% of antibody-positive patients underwent the required confirmatory RNA testing.
The Treatment Gap
- Among patients confirmed with active viremia, only 18.0% received a DAA prescription.
- Many asymptomatic individuals fail to consult a gastroenterologist after receiving screening letters.
- Automated reflex testing protocols are needed to bridge the gap between screening and treatment.

What Surveillance Protocol Protects Patients at Risk?

Patients diagnosed with chronic hepatitis B or C require lifelong surveillance. Even after achieving a virologic cure with DAAs, patients with pre-existing advanced fibrosis remain at risk for malignant transformation.

Standard Surveillance Guidelines
- Liver ultrasonography combined with serum alpha-fetoprotein (AFP) testing every 6 months.
- Periodic assessment of liver stiffness through elastography to track fibrosis progression.
- Regular viral load monitoring to detect breakthrough resistance or viral rebound.
Clinical Red Flags Requiring Immediate Escalation
- Sudden or unexplained weight loss accompanied by persistent right upper quadrant discomfort.
- New-onset jaundice, scleral icterus, or tea-colored urine.
- Development of ascites, peripheral edema, or unexplained abdominal distension.
- Hematemesis or melena, indicating bleeding from gastroesophageal varices.

Liver cancer is largely preventable when viral triggers are diagnosed early and suppressed completely. Relying solely on normal liver enzymes or blaming alcohol consumption obscures the primary clinical target. Proactive viral testing and timely antiviral therapy remain the definitive pathway to reducing liver cancer mortality worldwide.

Medical Disclaimer: This article is intended solely for educational and informational purposes and does not constitute formal medical advice. Individual diagnosis, clinical staging, and treatment protocols for chronic viral hepatitis and hepatocellular carcinoma must be determined by a qualified gastroenterologist or hepatologist.

https://health.chosun.com/site/data/html_dir/2026/10/20/2026102002276.html